What is B. Riley’s Estimate for VKTX Q4 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at B. Riley issued their Q4 2024 earnings estimates for shares of Viking Therapeutics in a research report issued on Thursday, November 21st. B. Riley analyst M. Mamtani anticipates that the biotechnology company will earn ($0.24) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same period last year, the firm earned ($0.23) EPS.

A number of other equities analysts have also commented on the stock. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. HC Wainwright lifted their price target on shares of Viking Therapeutics from $90.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, November 4th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $105.00 price objective on shares of Viking Therapeutics in a report on Thursday, September 12th. Finally, JPMorgan Chase & Co. assumed coverage on Viking Therapeutics in a report on Wednesday, September 11th. They set an “overweight” rating and a $80.00 target price on the stock. One research analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $109.73.

Viking Therapeutics Stock Performance

VKTX opened at $52.59 on Monday. The stock has a fifty day moving average of $63.73 and a 200-day moving average of $60.25. The company has a market capitalization of $5.86 billion, a P/E ratio of -56.55 and a beta of 1.00. Viking Therapeutics has a fifty-two week low of $11.55 and a fifty-two week high of $99.41.

Insider Activity

In related news, Director Sarah Kathryn Rouan sold 11,000 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $80.89, for a total transaction of $889,790.00. Following the sale, the director now owns 9,500 shares of the company’s stock, valued at $768,455. This trade represents a 53.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Brian Lian sold 216,130 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $70.83, for a total value of $15,308,487.90. Following the completion of the transaction, the chief executive officer now directly owns 2,304,927 shares of the company’s stock, valued at approximately $163,257,979.41. The trade was a 8.57 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 371,117 shares of company stock worth $27,140,009. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Viking Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Second Line Capital LLC raised its stake in shares of Viking Therapeutics by 34.1% during the third quarter. Second Line Capital LLC now owns 38,118 shares of the biotechnology company’s stock valued at $2,413,000 after acquiring an additional 9,699 shares during the last quarter. Vestcor Inc acquired a new stake in Viking Therapeutics in the third quarter valued at $741,000. M&T Bank Corp acquired a new stake in Viking Therapeutics in the third quarter valued at $354,000. Public Employees Retirement System of Ohio raised its position in Viking Therapeutics by 12.9% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 45,252 shares of the biotechnology company’s stock worth $2,865,000 after purchasing an additional 5,155 shares during the last quarter. Finally, MML Investors Services LLC lifted its holdings in Viking Therapeutics by 193.1% during the 3rd quarter. MML Investors Services LLC now owns 20,352 shares of the biotechnology company’s stock worth $1,288,000 after buying an additional 13,409 shares during the period. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.